OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea flag South Korea · Delayed Price · Currency is KRW
94,800
+5,300 (5.92%)
Jul 31, 2026, 3:30 PM KST

OliX Pharmaceuticals Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
11,0566,3593,88311,9834,93034,337
Short-Term Investments
87,76991,900-10,00053,00015,000
Trading Asset Securities
9,56934,2558,5313,9423,941420.68
Cash & Short-Term Investments
108,394132,51312,41425,92561,87249,757
Cash Growth
839.66%967.42%-52.11%-58.10%24.35%-26.95%
Accounts Receivable
-05,12795.113,55853.23-
Other Receivables
1,8211,115907.841,419996.88272.13
Receivables
1,8216,2421,0034,9771,050491.49
Inventory
418.41396.71554.26468.41657.17374.13
Prepaid Expenses
1,8841,5661,370244.91,3671,480
Other Current Assets
19,662134.21192.88526.8699136.92
Total Current Assets
132,179140,85115,53432,14265,04652,240
Property, Plant & Equipment
50,49250,49951,38543,91037,23231,525
Long-Term Investments
1,3921,3521,98623,48126,8090.5
Other Intangible Assets
1,9191,9441,7051,9812,1072,134
Other Long-Term Assets
367.51719.66639.621,3121,458772.05
Total Assets
186,349195,36671,249102,825132,65186,672

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accrued Expenses
400.78738.78488.52465.36358.62297.85
Short-Term Debt
-64413,441---
Current Portion of Long-Term Debt
3,5713,5713,572-19,23016,405
Current Portion of Leases
423.76318.3745.851,065939.87487.8
Current Income Taxes Payable
-2.8153.77---
Other Current Liabilities
15,65016,05111,7595,03319,01423,174
Total Current Liabilities
20,04621,32630,0606,56339,54340,365
Long-Term Debt
16,96417,85721,42835,36220,00020,326
Long-Term Leases
834.15895.925.382,9303,82651.69
Pension & Post-Retirement Benefits
--414.47--225.41
Other Long-Term Liabilities
3,1155,208867.987,6343,0806,296
Total Liabilities
40,95945,28752,77752,48966,44967,265

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
10,15010,0959,2308,0106,8526,852
Additional Paid-In Capital
327,654323,423175,533157,177151,89592,908
Retained Earnings
-201,378-191,586-167,785-122,910-103,224-84,303
Comprehensive Income & Other
7,2526,458871.877,1418,8853,064
Total Common Equity
143,678148,39017,84949,41864,40718,521
Minority Interest
721.77699.37623.76481.45295.16886.27
Shareholders' Equity
145,390150,07918,47350,33666,20319,407
Total Liabilities & Equity
186,349195,36671,249102,825132,65186,672

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
21,79323,28739,19239,35743,99637,271
Net Cash (Debt)
86,601109,227-26,778-13,43317,87612,487
Net Cash Growth
----43.16%-76.70%
Net Cash Per Share
4215.715553.79-1589.86-930.931304.50912.36
Filing Date Shares Outstanding
20.320.1918.4616.0213.713.7
Total Common Shares Outstanding
20.320.1918.4616.0213.713.7
Working Capital
112,133119,525-14,52625,57825,50211,874
Book Value Per Share
7077.557349.70966.923084.794700.191351.59
Tangible Book Value
141,759146,44516,14447,43762,30016,387
Tangible Book Value Per Share
6983.017253.40874.552961.164546.391195.84
Land
25,32525,32525,46025,74025,74025,740
Buildings
22,69022,69023,0333,3543,3543,354
Machinery
8,1607,6597,4256,4365,5184,427
Construction In Progress
158169.57-8,9481,23971.73